Mechanism of Action
Preventing and Repairing Oxidative Damage
Reactive metal ions play a key role in catalyzing oxidative stress which is the cause of most degenerative ocular diseases. Iron (Fe⁺⁺⁺) is the catalyst for reactive oxygen species which begin the disease pathology, causing damaged lipids and proteins. Another reactive metal ion, calcium (Ca⁺⁺), then binds those damaged lipids and proteins into aggregates, resulting in tissue damage. Removing these reactive ions BOTH improves vision and alleviates the disease progression.
Breakthrough Formulation
Chakshu is applying a breakthrough combination of molecules which are a powerful chelating agent and a permeation enhancer to address these reactive metal ions.
Chelation – Chelation is a well-understood process of attracting and removing metal ions. This ingredient, therefore, is able to remove both excess Fe⁺⁺⁺ and excess Ca⁺⁺. By removing Fe⁺⁺⁺, the disease pathology is inhibited. Tissue damage is alleviated by removing Ca⁺⁺, because excess Ca⁺⁺ binds damaged lipids and proteins.
Drug Permeation - The key scientific breakthrough in this formulation is the discovery of pairing a permeation enhancer molecule with the chelating molecule. Because chelating agents may sometimes be prohibited from passing through membranes; their effect, functioning alone, has been inconsistent. This is compounded by the imperviousness of the protective membranes in the eye. The drug permeation enhancer, however, allows the chelating molecule to enter all parts of the eye; thereby providing consistent chelating functionality.
Regional Chelation Therapy – Effective Drug Delivery
Chakshu has focused on providing a convenient self-administered eyedrop. This regional basis of treatment is more effective than systemic delivery and is possible because of the permeation enhancer. Therefore, the introduction of Regional Chelation Therapy (RCT) provides a localized treatment with consistent and predictable therapy.